Drug Description in Trials / DrugBank / KEGG DRUG


Search results


No. 薬物名(臨床試験情報から抽出) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY
On map, Yellow: Drug target genes
指定難病告示番号
1J-tube----1件: 6
2J01GB01----1件: 299
3J05A F01----1件: 135
4J05AG04----1件: 18
5J07AH07----1件: 14
6J1081----1件: 56
7J695----1件: 96
8J695, BSF 415977 (formerly LU415977), WAY-165772, A-796874.0----1件: 96
9JAK 3----1件: 46
10JAK 3 Ritlecitinib----1件: 46
11JAK Inhibitor----1件: 50
12JAK1 / JAK2 Inhibitor----1件: 46
13JAK1 / JAK2 Inhibtor----1件: 46
14Jaktinib Dihydrochloride Monohydrate 50mg BID and Mimic tablets of jakitinib hydrochloride 75mg BID and Acetylcysteine Effervescent Tablets1件: Acetylcysteine1件: D00221 --1件: 85
15Jaktinib Dihydrochloride Monohydrate 75mg BID and Mimic tablets of jakitinib hydrochloride 50mg BID and Acetylcysteine Effervescent Tablets1件: Acetylcysteine1件: D00221 --1件: 85
16Jaktinib Hydrochloride Tablets----1件: 271
17Janus Kinase Inhibitor----1件: 97
18Jardiance1件: Empagliflozin1件: D10459 --1件: 65
19JBPOS01011件: JBPOS0101---1件: 145
20JBT-101----4件: 49, 50, 51, 299
21JBT-101 (lenabasum)----1件: 299
22Jejunal extension tube----1件: 6
23Jejunal extension tube (J-tube)----1件: 6
24Jevity 1.0----1件: 2
25Jevity 1.5----1件: 2
26JHL1101----1件: 46
27Jianpixiaozhong particles and Wuse Dietotherapy----1件: 222
28Jin-shui Huan-xian granule----1件: 85
29Jinarc1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67
30JINARC - 15 MG +45 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28X15 MG + 28 X 45 MG)1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67
31JINARC - 15 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67
32JINARC - 30 MG + 60 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 60 MG)1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67
33JINARC - 30 MG +90 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 90 MG)1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67
34JINARC - 30 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67
35Jinarc - Tolvaptan tablets1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67
36Jinarc 15 mg tablets, Jinarc 45 mg tablets1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67
37Jinarc 30 mg Tablet1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67
38Jinarc 30 mg tablets, 90 mg tablets1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67
39Jinarc 30 mg tablets, Jinarc 60 mg tablets1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67
40Jinarc® 15mg Tablet1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67
41Jinarc® 30 Tablet1件: Tolvaptan1件: D01213 1件: AVPR2 💬3件: Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬1件: 67
42Jing Si Herbal Tea LIQUID PACKETS----2件: 46, 271
43Jintropin AQ----1件: 78
44JKB-122----1件: 95
45JKB-122 in capsule or tablet form----1件: 95
46JM----2件: 6, 13
47JM-010----1件: 6
48JM-010 group A----1件: 6
49JM-010 group B----1件: 6
50JM-4----1件: 13
51JNJ 38518168----1件: 46
52JnJ 54767414----1件: 28
53JNJ-16240159-AAC----1件: 46
54JNJ-31001074----1件: 6
55JNJ-38518168----1件: 46
56JNJ-38518168 (10 mg)----1件: 46
57JNJ-38518168 (3 mg)----1件: 46
58JNJ-38518168 (30 mg)----1件: 46
59JNJ-38518168 / MTX----1件: 46
60JNJ-38518168 50-mg Over Encapsulated Tablet----1件: 46
61JNJ-38518168-AEK - Over Encapsulated Tablet - 50 mg----1件: 46
62JNJ-38518168-ZBQ----1件: 46
63JNJ-38518168-ZBQ - film-coated tablet - 10 mg----1件: 46
64JNJ-38518168-ZBQ - film-coated tablet - 10mg----1件: 46
65JNJ-38518168-ZBQ - film-coated tablet - 3 mg----1件: 46
66JNJ-38518168-ZBQ - film-coated tablet - 30 mg----1件: 46
67JNJ-38518168-ZBQ - film-coated tablet - 30mg----1件: 46
68JNJ-38518168-ZBQ - film-coated tablet - 3mg----1件: 46
69JNJ-39039039----1件: 210
70JNJ-39758979----1件: 46
71JNJ-39758979 (10 mg)----1件: 46
72JNJ-39758979 (100 mg)----1件: 46
73JNJ-39758979 (30 mg)----1件: 46
74JNJ-39758979 (300 mg)----1件: 46
75JNJ-39758979 / MTX----1件: 46
76JNJ-39758979-AAC - enteric coated tablet - 10 mg----1件: 46
77JNJ-39758979-AAC - enteric coated tablet - 100 mg----1件: 46
78JNJ-39758979-AAC - enteric coated tablet - 30 mg----1件: 46
79JNJ-403465271件: JNJ-40346527---2件: 46, 96
80JNJ-40346527-AAC1件: JNJ-40346527---1件: 96
81JNJ-40346527-AAC - capsule - 50 mg1件: JNJ-40346527---1件: 46
82JNJ-42160443----1件: 226
83JNJ-54767414----2件: 28, 49
84JNJ-54781532 150 mg once daily----1件: 97
85JNJ-54781532 25 mg once daily----1件: 97
86JNJ-54781532 75 mg once daily----1件: 97
87JNJ-54781532 75 mg twice daily----1件: 97
88JNJ-54781532-AAD-10 mg----1件: 97
89JNJ-54781532-AAD-30 mg----1件: 97
90JNJ-54781532-AAD-5 mg----1件: 97
91JNJ-55920839----1件: 49
92JNJ-56022473----1件: 49
93JNJ-64304500----1件: 96
94JNJ-64304500-AAA----1件: 96
95JNJ-66525433----1件: 97
96JNJ-67484703----1件: 46
97JNJ-67864238----1件: 96
98JNJ-67896049----1件: 86
99JNJ-67896049 (ACT-293987)----1件: 86
100JNJ-67896062 / ACT-064992----2件: 86, 88
101JNJ-67896062/ ACT-064992----2件: 86, 88
102JNJ-72537634----1件: 97
103JNJ-78934804----2件: 96, 97
104JNJ-80202135----4件: 11, 46, 49, 53
105JNJ31-31001074----1件: 6
106Jojoba oil1件: Jojoba oil---1件: 36
107Jojoba oil with broccoli sprout extract2件: Broccoli,
Jojoba oil
---1件: 36
108Jorveza1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
109Jorveza 0.5 mg compresse orodispersibili1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
110Jorveza 0.5 mg orodispersible tablets1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
111Jorveza 1 mg compresse orodispersibili1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
112Jorveza 1 mg orodispersible tablets1件: Budesonide1件: D00246 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 98
113JP 1730----1件: 6
114JP-1730/F01----2件: 6, 17
115JP-1730/F02----2件: 6, 17
116JP-1730/F03----2件: 6, 17
117JR-141----1件: 19
118JR-141 or Idursulfase1件: Idursulfase1件: D04499 1件: IDS 💬3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬1件: 19
119JR-171----1件: 19
120JS002----1件: 79
121JS005----1件: 271
122JSP191----1件: 285
123JTE-051----1件: 46
124JTT-251----1件: 86
125Juanbi pill----1件: 46
126Juvit D3----1件: 6
127Jyseleca1件: Filgotinib1件: D10871 1件: JAK1 💬27件: Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46
128Jyseleca 100 mg film-coated tablets1件: Filgotinib1件: D10871 1件: JAK1 💬27件: Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46
129Jyseleca 200 mg film-coated tablets1件: Filgotinib1件: D10871 1件: JAK1 💬27件: Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46
130JZP-110----1件: 6